Status:
WITHDRAWN
Molecular Markers in Cancers and Precancers (MOCA)
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Cancer
Precancerous Lesion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In oncology, the search for genetic alterations or infectious agents in tumour tissues has become a major medical challenge for diagnosis, prognosis, prediction of response to treatment and in particu...
Detailed Description
It is in this context the prescription of targeted therapies is now conditioned by the identification of specific genetic anomalies in the tumour. As such, kinase inhibitors have been shown to be effe...
Eligibility Criteria
Inclusion
- Male and female patients with or without a precancerous lesion or cancer
- Patients covered by a social security plan
- Patients who have given their consent
Exclusion
- Patient in emergency situation
- Contraindication to tissue, cell, blood or other biological fluid collection
- Subject unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator
- Legal incapacity or limited legal capacity Subject is within the exclusion period of another study or is on the "National Volunteer Registry".
Key Trial Info
Start Date :
October 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05257707
Start Date
October 5 2022
End Date
December 31 2023
Last Update
July 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Besançon
Besançon, France, 25000